Literature DB >> 15334182

The inhibition of gamma-secretase as a therapeutic approach to Alzheimer's disease.

Taisuke Tomita1, Takeshi Iwatsubo.   

Abstract

Alzheimer's disease is a dementing neurodegenerative disorder for which there is no effective treatment at present. Genetic and biological studies provide evidence that the production and deposition of amyloid-beta peptides (Abeta contribute to the etiology of Alzheimer's disease. gamma-Secretase is the pivotal enzyme in generating the C terminus of Abeta which determines its aggregability and speed of deposition. Drugs that regulate the production of Abeta by inhibiting gamma-secretase activity could provide an effective therapy for Alzheimer's disease, although recent studies suggest that gamma-secretase plays important roles in cellular signaling. This review focuses on studies of the gamma-secretase biology and provides the direction for developing effective and selective gamma-secretase inhibitors as drugs for the treatment of Alzheimer's disease. (c) 2004 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15334182     DOI: 10.1358/dnp.2004.17.5.829036

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  10 in total

Review 1.  Eph/ephrin signaling: networks.

Authors:  Dina Arvanitis; Alice Davy
Journal:  Genes Dev       Date:  2008-02-15       Impact factor: 11.361

2.  Intracellular ion channel CLIC1: involvement in microglia-mediated β-amyloid peptide(1-42) neurotoxicity.

Authors:  Stephen D Skaper; Laura Facci; Pietro Giusti
Journal:  Neurochem Res       Date:  2013-06-07       Impact factor: 3.996

3.  Cyclic cis-Locked Phospho-Dipeptides Reduce Entry of AβPP into Amyloidogenic Processing Pathway.

Authors:  Carolyn L Fisher; Ross J Resnick; Soumya De; Lucila A Acevedo; Kun Ping Lu; Frank C Schroeder; Linda K Nicholson
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

4.  Apoptosis-associated tyrosine kinase and neuronal cell death.

Authors:  Jane P Hughes; Daniel R Ward; Laura Facci; Jill C Richardson; Stephen D Skaper
Journal:  Neurochem Res       Date:  2009-11-26       Impact factor: 3.996

5.  Reduced amyloid deposition in mice overexpressing RTN3 is adversely affected by preformed dystrophic neurites.

Authors:  Qi Shi; Marguerite Prior; Wanxia He; Xiangying Tang; Xiangyou Hu; Riqiang Yan
Journal:  J Neurosci       Date:  2009-07-22       Impact factor: 6.167

6.  Antisense directed against PS-1 gene decreases brain oxidative markers in aged senescence accelerated mice (SAMP8) and reverses learning and memory impairment: a proteomics study.

Authors:  Ada Fiorini; Rukhsana Sultana; Sarah Förster; Marzia Perluigi; Giovanna Cenini; Chiara Cini; Jian Cai; Jon B Klein; Susan A Farr; Michael L Niehoff; John E Morley; Vijaya B Kumar; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2013-06-15       Impact factor: 7.376

Review 7.  Potential therapeutic approaches for modulating expression and accumulation of defective lamin A in laminopathies and age-related diseases.

Authors:  Alex Zhavoronkov; Zeljka Smit-McBride; Kieran J Guinan; Maria Litovchenko; Alexey Moskalev
Journal:  J Mol Med (Berl)       Date:  2012-10-23       Impact factor: 4.599

8.  Presenilin-dependent intramembrane cleavage of ephrin-B1.

Authors:  Taisuke Tomita; Sayaka Tanaka; Yuichi Morohashi; Takeshi Iwatsubo
Journal:  Mol Neurodegener       Date:  2006-06-12       Impact factor: 14.195

9.  Bax inhibitor 1 is a γ-secretase-independent presenilin-binding protein.

Authors:  Shenjie Wu; Wenqi Song; Catherine C L Wong; Yigong Shi
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-17       Impact factor: 11.205

Review 10.  Neurodegenerative Diseases: Implications of Environmental and Climatic Influences on Neurotransmitters and Neuronal Hormones Activities.

Authors:  Emmanuel A Ayeni; Ahmad M Aldossary; Daniel A Ayejoto; Lanre A Gbadegesin; Abdullah A Alshehri; Haya A Alfassam; Henok K Afewerky; Fahad A Almughem; Saidu M Bello; Essam A Tawfik
Journal:  Int J Environ Res Public Health       Date:  2022-09-30       Impact factor: 4.614

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.